| A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (NCT05126758) | Capricor Inc. | 2022-06-22 |
| Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations (NCT05833633) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-03-18 |
| Characterization of DupEx2 Duchenne Muscular Dystrophy (NCT06337669) | IRCCS San Raffaele | 2022-01-31 |
| The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD (NCT05066633) | Medical University of Gdansk | 2021-08-18 |
| Regular Physical Exercise in Duchenne Muscular Dystrophy (NCT03963453) | Haukeland University Hospital | 2021-02-01 |
| A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) (NCT03992430) | Sarepta Therapeutics, Inc. | 2020-07-13 |
| Effects of Parental Influence on Physical Activity Level and Participation in Children With Duchenne Muscular Dystrophy (NCT05209087) | Hacettepe University | 2020-03-01 |
| Safety Study of BLS-M22 in Healthy Volunteers (NCT03789734) | BioLeaders Corporation | 2019-06-04 |
| An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) (NCT03675126) | Sarepta Therapeutics, Inc. | 2018-12-19 |
| A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) (NCT03769116) | Sarepta Therapeutics, Inc. | 2018-12-05 |
| Spironolactone Versus Prednisolone in DMD (NCT03777319) | Kevin Flanigan | 2018-12-05 |
| Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (NCT03703882) | Catabasis Pharmaceuticals | 2018-10-02 |
| A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy (NCT03400852) | Mallinckrodt ARD LLC | 2018-07-27 |
| Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography (NCT03490214) | University of Erlangen-Nürnberg Medical School | 2018-06-01 |
| The Effects of Trunk Exercises on Upper Extremity and Respiratory Functions in DMD (NCT04669847) | Gokce Yagmur Gunes Gencer | 2018-04-07 |
| A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (NCT03406780) | Capricor Inc. | 2018-04-04 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) (NCT03375255) | Sarepta Therapeutics, Inc. | 2018-02-05 |
| Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy (NCT03179631) | PTC Therapeutics | 2017-07-06 |
| User-centred Assistive System for Arm Functions in Neuromuscular Subjects (NCT03127241) | Politecnico di Milano | 2017-06-16 |
| Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD (NCT02834650) | Stanford University | 2017-02-01 |
| Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy (NCT02439216) | Catabasis Pharmaceuticals | 2016-04-01 |
| Rimeporide in Patients With Duchenne Muscular Dystrophy (NCT02710591) | EspeRare Foundation | 2016-03-01 |
| Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) (NCT02369731) | PTC Therapeutics | 2015-04-30 |
| Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet (NCT02383511) | Summit Therapeutics | 2015-02-01 |
| Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy (NCT02286947) | Sarepta Therapeutics, Inc. | 2014-11-01 |
| An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy (NCT02090959) | PTC Therapeutics | 2014-03-20 |
| Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy (NCT02195999) | University of Florida | 2013-12-01 |
| A Study of Tadalafil for Duchenne Muscular Dystrophy (NCT01865084) | Eli Lilly and Company | 2013-09-01 |
| Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy (NCT01918384) | Kobe University | 2013-08-01 |
| Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) (NCT01826487) | PTC Therapeutics | 2013-03-26 |
| Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients (NCT01826422) | Coordinación de Investigación en Salud, Mexico | 2013-03-01 |
| Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy (NCT01506518) | University of North Carolina, Chapel Hill | 2012-01-01 |
| Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (NCT01027884) | Santhera Pharmaceuticals | 2009-07-01 |
| Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy (NCT00296621) | Assistance Publique - Hôpitaux de Paris | 2006-02-01 |
| Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy (NCT00243789) | Cooperative International Neuromuscular Research Group | 2005-09-01 |
| Pentoxifylline in Duchenne Muscular Dystrophy (NCT00102453) | Cooperative International Neuromuscular Research Group | 2002-03-01 |
| KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy (NCT00033813) | Cooperative International Neuromuscular Research Group | 2002-01-01 |
| An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy (NCT00033189) | Cooperative International Neuromuscular Research Group | 2001-09-01 |
| Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping (NCT07250737) | Avidity Biosciences, Inc. | |
| A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD) (NCT00018109) | National Center for Research Resources (NCRR) | |
| The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation (NCT04337112) | NS Pharma, Inc. | |